Posted inClinical Updates Dermatology news Specialties
Once-Daily Oral Icotrokinra vs Placebo and Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: Insights from ICONIC-ADVANCE 1 & 2 Phase 3 Trials
ICONIC-ADVANCE 1 & 2 phase 3 trials demonstrate that once-daily oral icotrokinra significantly improves skin clearance with superior efficacy and favorable safety compared to placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
